Tipranavir


Thông tin thuốc gốc
Chỉ định và Liều dùng
Oral
HIV-1 infection
Adult: In combination with ritonavir in treatment-experienced patients, resistant to other protease inhibitors: 500 mg bid.
Suy gan
Moderate to severe (Child-Pugh class B or C): Contraindicated.
Cách dùng
Should be taken with food.
Chống chỉ định
Hypersensitivity. Moderate to severe hepatic impairment (Child-Pugh class B or C). Lactation. Concomitant administration with drugs that highly dependent on CYP3A for clearance or potent CYP3A inducers.
Thận trọng
Patient with diabetes mellitus, haemophilia A or B, risk factor for increased bleeding (e.g. trauma, surgery, other pathological conditions); sulfonamide allergy. Mild hepatic impairment (including chronic hepatitis B or C). Pregnancy.
Tác dụng không mong muốn
Significant: Fat redistribution (e.g. buffalo hump, breast enlargement, central obesity, cushingoid appearance, facial wasting, peripheral wasting), hyperglycaemia or diabetes mellitus, hyperlipidaemia, immune reconstitution syndrome, skin reaction (e.g. urticarial rash, maculopapular rash, photosensitivity).
Gastrointestinal disorders: Abdominal distention, abdominal pain, diarrhoea, dyspepsia, flatulence, nausea, vomiting.
General disorders and admin site conditions: Fatigue.
Metabolism and nutrition disorders: Hypertriglyceridaemia.
Nervous system disorders: Headache.
Potentially Fatal: Hepatotoxicity (e.g. hepatitis, hepatic failure), intracranial haemorrhage.
Chỉ số theo dõi
Monitor total cholesterol and triglyceride at baseline and during therapy; LFT at baseline and frequently during therapy; viral load, CD4, glucose as clinically indicated. Monitor for signs and symptoms of hepatitis/hepatotoxicity.
Tương tác
Increased serum concentration with fluconazole. May increase serum concentration of bosentan, fluticasone, midazolam (IV), rifabutin, trazodone, atorvastatin. Increased risk of QT prolongation, palpitations, sinus tachycardia with salmeterol. Decreased serum concentration with anticonvulsants (e.g. carbamazepine, phenobarbital, phenytoin). May decrease serum concentration of ethinyl estradiol, nucleoside reverse transcriptase inhibitors (e.g. abacavir, didanosine, zidovudine), protease inhibitors (e.g. amprenavir, lopinavir, saquinavir), dolutegravir, meperidine. May produce disulfiram-like reaction with metronidazole.
Potentially Fatal: May increase plasma concentration and increase risk of serious adverse events of drugs highly dependent on CYP3A for clearance or potent CYP3A inducers (e.g. alfuzosin; antiarrhythmics [e.g. amiodarone, bepridil, flecainide, propafenone, quinidine]; ergot derivatives [e.g. dihydroergotamine, ergonovine, ergotamine, methylergonovine]; rifampicin, cisapride; HMG-CoA reductase inhibitors [e.g. lovastatin, simvastatin]; antipsychotics (e.g. pimozide, lurasidone]; sildenafil; sedative/hypnotic [e.g. oral midazolam, triazolam].
Tương tác với thức ăn
Decreased plasma concentration with St. John's wort, avoid use.
Tác dụng
Description: Tipranavir is a non-peptide protease inhibitor which binds to HIV-1 protease activity site and prevents cleavage of viral Gag-Pol polyprotein precursors into individual functional proteins. Thus, resulting in the formation of immature, non-infectious viral particles.
Pharmacokinetics:
Absorption: Limited absorption after oral administration. Time to peak plasma concentration: Approx 1-5 hours.
Distribution: Crosses the placenta. Volume of distribution: 7.7-10.2 L. Plasma protein binding: >99.9% to albumin and α1- acid glycoprotein.
Metabolism: Metabolised in the liver mainly by CYP3A4.
Excretion: Mainly via faeces (82.3%); urine (4.4 %). Elimination half-life: 5.5 hours (females); 6 hours (males).
Đặc tính

Chemical Structure Image
Tipranavir

Source: National Center for Biotechnology Information. PubChem Compound Summary for CID 54682461, Tipranavir. https://pubchem.ncbi.nlm.nih.gov/compound/Tipranavir. Accessed Dec. 21, 2020.

Bảo quản
Cap: Store between 2-8°C. Do not freeze. Oral solution: Store between 15-25°C. Do not refrigerate or freeze.
Phân loại MIMS
Thuốc kháng virus
Phân loại ATC
J05AE09 - tipranavir ; Belongs to the class of protease inhibitors. Used in the systemic treatment of viral infections.
Tài liệu tham khảo
Anon. Tipranavir. AHFS Clinical Drug Information [online]. Bethesda, MD. American Society of Health-System Pharmacists, Inc. https://www.ahfscdi.com. Accessed 21/10/2020.

Anon. Tipranavir. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 21/10/2020.

Aptivus Capsules, Liquid Filled, Solution (Boehringer Ingelheim Pharmaceuticals, Inc.). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/. Accessed 23/10/2020.

Buckingham R (ed). Tipranavir. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 21/10/2020.

Joint Formulary Committee. Tipranavir. British National Formulary [online]. London. BMJ Group and Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 21/10/2020.

Thông báo miễn trừ trách nhiệm: Thông tin này được MIMS biên soạn một cách độc lập dựa trên thông tin của Tipranavir từ nhiều nguồn tài liệu tham khảo và được cung cấp chỉ cho mục đích tham khảo. Việc sử dụng điều trị và thông tin kê toa có thể khác nhau giữa các quốc gia. Vui lòng tham khảo thông tin sản phẩm trong MIMS để biết thông tin kê toa cụ thể đã qua phê duyệt ở quốc gia đó. Mặc dù đã rất nỗ lực để đảm bảo nội dung được chính xác nhưng MIMS sẽ không chịu trách nhiệm hoặc nghĩa vụ pháp lý cho bất kỳ yêu cầu bồi thường hay thiệt hại nào phát sinh do việc sử dụng hoặc sử dụng sai các thông tin ở đây, về nội dung thông tin hoặc về sự thiếu sót thông tin, hoặc về thông tin khác. © 2022 MIMS. Bản quyền thuộc về MIMS. Phát triển bởi MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in